Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Sees Large Volume Increase – What’s Next?

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) saw unusually-high trading volume on Wednesday. Approximately 1,968,625 shares traded hands during mid-day trading, an increase of 152% from the average daily volume of 780,809 shares. The stock last traded at $22.0640 and had previously closed at $22.74.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on FMS shares. Citigroup reiterated a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Friday, July 17th. BNP Paribas Exane downgraded Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating and set a $19.90 price objective for the company. in a research note on Tuesday, July 28th. Zacks Research cut Fresenius Medical Care AG & Co. KGaA from a “hold” rating to a “strong sell” rating in a report on Thursday, October 15th. Sanford C. Bernstein boosted their target price on Fresenius Medical Care AG & Co. KGaA from $25.50 to $25.80 and gave the stock a “market perform” rating in a research report on Thursday, August 6th. Finally, Barclays downgraded Fresenius Medical Care AG & Co. KGaA from an “equal weight” rating to an “underweight” rating in a research report on Monday. Seven research analysts have rated the stock with a Hold rating and five have issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce” and an average price target of $23.42.

Fresenius Medical Care AG & Co. KGaA Trading Up 2.5%

The business has a fifty day simple moving average of $22.30 and a 200 day simple moving average of $22.91. The stock has a market cap of $11.79 billion, a price-to-earnings ratio of 12.77, a PEG ratio of 5.14 and a beta of 0.78. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.69 and a current ratio of 0.99.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last issued its quarterly earnings data on Tuesday, November 3rd. The company reported $0.64 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.65 by ($0.01). The company had revenue of $5.59 billion during the quarter, compared to analysts’ expectations of $5.52 billion. Fresenius Medical Care AG & Co. KGaA had a net margin of 4.23% and a return on equity of 9.08%. As a group, equities analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 2.27 EPS for the current year.

Institutional Investors Weigh In On Fresenius Medical Care AG & Co. KGaA

Several hedge funds have recently made changes to their positions in the business. Mather Group LLC. grew its position in shares of Fresenius Medical Care AG & Co. KGaA by 838.0% in the third quarter. Mather Group LLC. now owns 1,407 shares of the company’s stock valued at $31,000 after purchasing an additional 1,257 shares during the period. Farther Finance Advisors LLC boosted its stake in Fresenius Medical Care AG & Co. KGaA by 39.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,915 shares of the company’s stock worth $43,000 after buying an additional 538 shares during the last quarter. Allworth Financial LP grew its holdings in Fresenius Medical Care AG & Co. KGaA by 31.5% in the 2nd quarter. Allworth Financial LP now owns 3,552 shares of the company’s stock valued at $80,000 after buying an additional 850 shares during the period. Integrated Wealth Concepts LLC purchased a new stake in Fresenius Medical Care AG & Co. KGaA in the 2nd quarter valued at about $91,000. Finally, EverSource Wealth Advisors LLC increased its stake in shares of Fresenius Medical Care AG & Co. KGaA by 50.3% during the 1st quarter. EverSource Wealth Advisors LLC now owns 4,135 shares of the company’s stock valued at $93,000 after acquiring an additional 1,383 shares during the last quarter. Institutional investors and hedge funds own 8.37% of the company’s stock.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co. KGaA is a healthcare company focused on treating people with chronic kidney failure. It provides dialysis care through a global network of treatment centers and supports patients who receive care in clinics or at home. The company also develops and supplies products used in dialysis, including dialysis machines, dialyzers, and related medical equipment and materials. Its services include clinical care and support for healthcare providers involved in kidney treatment.